COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk We conducted a two-round modified Delphi survey. Participants were patients (or their carers) who had ...

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

PHOENIX — Patients treated for cancer with immune checkpoint inhibitors (ICIs) who develop the drugs’ known side effects of diarrhea and colitis experience increased risk of adenomas in the colon — ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Bottom Line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to ...

Checkpoint inhibitor-based therapy and ISRT may replace autologous transplant and high-dose chemotherapy in low-risk relapsed cHL, reducing side effects while maintaining EFS outcomes. The CheckMate ...

Humans have been attempting to combat cancer since the time of the Ancient Egyptians, and recent decades have seen remarkable progress. However, tumor cells have developed sophisticated ways to evade ...

Adding pembrolizumab to docetaxel failed to improve survival in metastatic castration-resistant prostate cancer. Overall survival was 19-20 months regardless of treatment arm, even in patients with PD ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...